**
Newly uncovered records indicate that senior officials from the Trump administration engaged in discussions with Bayer’s CEO Bill Anderson regarding legal strategies related to the controversial glyphosate herbicide prior to significant regulatory actions that appeared to favour the company’s position. The revelations raise critical questions about the intersection of corporate influence and public health policy.
Meeting of Key Players
On June 17, 2025, a pivotal meeting took place at the Environmental Protection Agency (EPA) involving Anderson and two other senior Bayer executives. The agenda included the discussion of litigation strategies, notably the company’s efforts to navigate numerous lawsuits alleging that its glyphosate products, including Roundup, are linked to cancer. These lawsuits, initiated by thousands of individuals, argue that Bayer failed to adequately warn consumers about the potential health risks associated with its herbicides.
Internal communications from the EPA reveal that the meeting was framed as an update on Bayer’s litigation status and potential labelling options. It was noted that discussions would encompass “supreme court action,” indicating a proactive approach by Bayer to influence regulatory perspectives ahead of an impending Supreme Court decision on its case.
Regulatory Support for Bayer
Subsequent to this meeting, the Trump administration took several steps that appeared to bolster Bayer’s legal standing. Notably, on December 1, 2025, the solicitor general appointed by the Trump administration, D John Sauer, urged the Supreme Court to hear Bayer’s appeal concerning its liability in the glyphosate lawsuits. This request was granted, with a hearing scheduled for April 27, 2026.
Moreover, in February 2026, the White House invoked the Defense Production Act to safeguard the production of glyphosate herbicides, effectively providing a form of immunity for manufacturers like Bayer. A further amicus brief filed by Sauer on March 2, 2026, explicitly backed Bayer’s case, showcasing a concerted effort by the administration to assist the company in its legal battles.
Implications of Corporate Influence
Critics of the Trump administration’s interactions with Bayer have expressed concern regarding the implications of such meetings on public health. Nathan Donley, an environmental health science director at the Center for Biological Diversity, stated, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.” This sentiment underscores a growing anxiety about the extent to which corporations can influence regulatory frameworks and the prioritisation of industry interests over citizen welfare.
Legal experts have voiced similar apprehensions. Whitney Di Bona, a consumer safety advocate, questioned whether the EPA offered the same platform to individuals suffering from the alleged effects of glyphosate, highlighting a potential imbalance in the regulatory process. Similarly, Naomi Oreskes, a Harvard professor, remarked that the meeting exemplifies a concerning trend in which corporate leaders gain access to government officials while the voices of the affected populace are largely unheard.
A Call for Transparency
Bayer, for its part, has characterised the meeting as a routine part of the regulatory process, asserting that it has maintained transparency regarding its position on glyphosate litigation. A spokesperson stated, “Such interactions are not limited to registrant companies and many other groups including NGOs similarly interface with regulatory agencies.” However, the lack of clarity surrounding the specific topics of discussion raises questions about the true nature of these engagements.
Activists like Zen Honeycutt, founder of Moms Across America, have long contended that chemical companies exert undue influence over regulatory bodies. Despite their efforts to engage with the EPA, they often find their requests for pesticide restrictions disregarded, further illustrating a potential disconnect between regulatory agencies and public health advocates.
Why it Matters
The implications of the Trump administration’s interactions with Bayer extend far beyond the courtroom. As the regulatory landscape evolves, the potential for corporate interests to dictate public health policy raises alarm bells for consumers and advocates alike. The revelations spotlight the urgent need for transparency and accountability within regulatory processes to ensure that public health is prioritised over corporate profit. The outcome of the Supreme Court’s deliberations on Bayer’s case could set a precedent with far-reaching consequences, potentially shaping the future of agricultural practices and consumer safety in the United States and beyond.
